Gyre Therapeutics, Inc. (NASDAQ:GYRE) Financings

Gyre Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Closed: US$23M raised · US$9 a share · Jefferies +1
Dealers: Jefferies (lead), H.C. Wainwright & Co.
Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes
May 29, 2025
Public offering of common stock
Announced: Jefferies +1
Dealers: Jefferies (lead), H.C. Wainwright & Co.
Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes
May 22, 2025

Read by 6ix AI from the company's releases

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Financings | 6ix